The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
A randomized, placebo-controlled trial of coenzyme Q 10 and remacemide in Huntington’s disease
Abstract
OBJECTIVES: To determine whether chronic treatment with coenzyme Q10 or remacemide hydrochloride slows the functional decline of early Huntington's disease (HD). METHODS: The authors conducted a multicenter, parallel group, double-blind, 2 x 2 factorial, randomized clinical trial. Research participants with early HD (n = 347) were randomized to receive coenzyme Q10 300 mg twice daily, remacemide hydrochloride 200 mg three times daily, both, or neither treatment, and were evaluated every 4 to 5 months for a total of 30 months on assigned treatment. The prespecified primary measure of efficacy was the change in total functional capacity (TFC) between baseline and 30 months. Safety measures included the frequency of clinical adverse events. RESULTS: Neither intervention significantly altered the decline in TFC. Patients treated with coenzyme Q10 showed a trend toward slowing in TFC decline (13%) over 30 months (2.40- versus 2.74-point decline, p = 0.15), as well as beneficial trends in some secondary measures. There was increased frequency of nausea, vomiting, and dizziness with remacemide and increased frequency of stomach upset with coenzyme Q10. CONCLUSIONS: Neither remacemide nor coenzyme Q10, at the dosages studied, produced significant slowing in functional decline in early HD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Administration of CoQ10 resulted in a 14% decrease in disease progression.”
From Mitochondrial Approaches for Neuroprotection (2008) · cites this paper as [155]
In the citing paper
“Remacemide demonstrated no efficacy.”
From Mitochondrial Approaches for Neuroprotection (2008) · cites this paper as [155]
In the citing paper
“This trial was powered to be able to determine a 40% attenuation of total functional capacity decline with 80% power.”
From Mitochondrial Approaches for Neuroprotection (2008) · cites this paper as [155]
Citations
Cites
Unified Huntington's disease rating scale: Reliability and consistency
Kremer, H. P. H. (1996) · Movement Disorders · doi:10.1002/mds.870110204 · Cited by 2,155
The hopkins verbal learning test: Development of a new memory test with six equivalent forms
Brandt, J. (1991) · Clinical Neuropsychologist · doi:10.1080/13854049108403297 · Cited by 1,317
Browne, S. E., Bowling, A. C., Macgarvey, U., Baik, M. J., Berger, S. C., Muquit, M. M. K., Bird, E. D., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410514 · Cited by 885
Huntington disease: Clinical care and evaluation
Shoulson, I., & Fahn, S. (1979) · Neurology · doi:10.1212/wnl.29.1.1 · Cited by 746
Energy metabolism defects in Huntington's disease and effects of coenzyme Q10
Koroshetz, W. J., Jenkins, B. G., Rosen, B. R., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410206 · Cited by 405
Rate of functional decline in Huntington’s disease
Marder, K., Zhao, H., Myers, R. H., Cudkowicz, M., Kayson, E., Kieburtz, K., Orme, C., Paulsen, J., Penney, J. B., Siemers, E., et al. (2000) · Neurology · doi:10.1212/wnl.54.2.452 · Cited by 362
Self-citationExpression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons
Ginsberg, S. D., Hemby, S. E., Lee, V. M. ‐., Eberwine, J. H., & Trojanowski, J. Q. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200007)48:1 · Cited by 315
Huntington's disease in venezuela: 7 years of follow‐up on symptomatic and asymptomatic individuals
Penney, J. B., Young, A. B., Shoulson, I., Starosta‐Rubinstein, S., Snodgrass, S. R., Sanchez‐Ramos, J., Ramos‐Arroyo, M. A., Gomez, F., Penchaszadeh, G. K., Alvir, J., et al. (1990) · Movement Disorders · doi:10.1002/mds.870050202 · Cited by 218
Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate
Beal, M. F., Henshaw, D. R., Jenkins, B. G., Rosen, B. R., & Schulz, J. B. (1994) · Annals of Neurology · doi:10.1002/ana.410360613 · Cited by 189
Dopaminergic neurons degenerate by apoptosis in Parkinson's disease
Hirsch, É. C., Hunot, S., Faucheux, B. A., Agid, Y., Mizuno, Y., Mochizuki, H., Tatton, W. G., Tatton, N. A., & Olanow, W. C. (1999) · Movement Disorders · doi:10.1002/1531-8257(199903)14:2 · Cited by 152
Flagged first, then by citations
Research works printed but not linked: 1
- Reitan RM Wolfson D. The Halstead–Reitan Neuropsychological Test Battery. Tuscon: Neuropsychology Press 1958.
Cited by
Sorted by citations
Items 301–311 of 311
Sontheimer, H. W. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800244-5.00007-0
The paradigm of Huntington’s disease: Therapeutic opportunities in neurodegeneration
Leegwater‐Kim, J., & Cha, J.-H. J. (2004) · Neurotherapeutics · doi:10.1007/bf03206573
Ceballos-Baumann, A., Schwarz, M., Wessel, K., & Weiland, T. (2011) · Springer eBooks · doi:10.1007/978-3-642-16920-5_41
(2006) · CRC Press eBooks · doi:10.1201/b14623-16
Malattia di Huntington: aspetti diagnostici attuali e applicazioni pratiche
Youssov, K., & Bachoud‐Lévi, A. (2018) · EMC - Neurologia · doi:10.1016/s1634-7072(18)89403-x
Vitamins, Minerals, Supplements and Dietary Approaches
(2002) · Focus on Alternative and Complementary Therapies · doi:10.1211/fact.2002.00112
Characterising the role of alpha synuclein in Ferroptosis, in the context of Parkinson's Disease
Mahoney‐Sanchez, L. (2022) · theses.fr (ABES) · doi:10.70675/a7f080d0z9ffaz4e1ez9550z0e29c4958e66
Liu, X., Bao, J., Yu, Z., Zheng, W., Huang, Y., Zhang, Y., & Jiang, X. (2026) · Antioxidants · doi:10.3390/antiox15101219
Dumała, S., Jędrzejewska, A., Kwaśniak-Butowska, M., Sousa, P. A. D., & Tomczyk, M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1984341
Kremer, H. P. H. (2009) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-8061-9_23
Metadata
- Authors
- The Huntington Study Group
- Corresponding author
- The Huntington Study Group
- Venue
- Neurology
- Published
- 2001-08-14
- Volume
- 57
- Issue
- 3
- Pages
- 397-404
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W4245847463
- Cited by
- 312
- References
- 19
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 4 · 2023: 5 · 2022: 8 · 2021: 10 · 2020: 8 · 2019: 9 · 2018: 12 · 2017: 11 · 2016: 11 · 2015: 3 · 2014: 9 · 2013: 5 · 2012: 16
- FWCI
- 7.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Neurological Disorders and Stroke (NS R01-35284, R01NS035284)
- National Center for Research Resources (RR-00044, RR 01066, RR 07122, M01RR001066, M01RR000044, RR00042, RR 00645, M01RR000042, M01RR000645)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Keywords
- Huntington's disease, coenzyme Q10, remacemide, functional decline, total functional capacity, disease-modifying therapy, early-stage Huntington's disease, adverse events, nausea and vomiting
- MeSH terms
- Acetamides, Adult, Coenzymes, Double-Blind Method, Female, Humans, Huntington Disease, Male, Middle Aged, Prognosis, Time Factors, Ubiquinone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
